Earnings Report Card: The 15-Cent Story Wall Street Keeps Missing

The article says S&P 500 companies’ profit margins rose to about 15.7 cents per sales dollar, with gains concentrated in Technology (~31 cents) and Communication Services (~28 cents), while Health Care stays near 6 cents. It lists “bullish” and “bearish” earnings-watch stocks, highlighting Marathon Petroleum (MPC) and Diamondback Energy (FANG) versus Constellation Energy (CEG) and Vistra (VST).

Original reporting
Published Aug 1, 2026, 1:18 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 1, 2026, 5:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Earnings Report Card: The 15-Cent Story Wall Street Keeps Missing — source image
Decision brief

The 30-second read

$APOBullishLow
01

Why it matters

It offers a pre-earnings positioning checklist (bullish and bearish screens) and highlights a few large expected quarter-over-quarter EPS swings, especially for Marathon Petroleum and Constellation Energy.

02

Market read

For traders, the actionable element is the author’s specific pre-earnings watchlist and the magnitude/direction of expected EPS changes, not a new corporate event.

03

What to watch

The piece does not provide guidance details, cash flow, or balance-sheet changes for the named companies, so traders may over-weight EPS rebound magnitude versus sustainability and revisions.

Relevance 4/10Novelty 3/10Timing: ahead of next week’s earnings reports for the listed names

Background

The article frames S&P 500 profitability as at a record level and then narrows to sector margin dispersion, followed by two analyst-EPS screens for upcoming earnings.

Company-level read

Ticker impact

$APOBullishMedium confidence
Context

The article lists Apollo Global as expected to flip from a prior-quarter loss to a profit, implying a potential earnings-driven repricing next week.

Expected impact

Moderate upside bias into the report if the rebound is realized; otherwise risk of mean reversion.

Evidence & confidence

The text provides directional EPS swing expectations (loss to profit) but no new company-specific disclosure beyond the screen.

$EXPEBullishMedium confidence
Context

Expedia Group is included in the bullish screen, expected to move from a prior-quarter loss to a profit, setting up a potential positive earnings surprise.

Expected impact

Mild-to-moderate positive reaction likelihood if EPS beats and guidance is not impaired.

Evidence & confidence

The article frames EXPE as meeting analyst-coverage and EPS-improvement criteria, but does not provide fresh guidance or filings.

$WATBullishMedium confidence
Context

Waters Corp. appears on the bullish list, expected to go from red ink to black versus the previous quarter.

Expected impact

Moderate upside bias into earnings, contingent on the magnitude of the rebound.

Evidence & confidence

The article provides directional EPS improvement but no additional fundamental catalyst or new disclosure.

$CRLBullishMedium confidence
Context

Charles River Laboratories is flagged as expected to improve from a prior-quarter loss to a profit, making it a candidate for earnings-driven upside.

Expected impact

Moderate upside bias if results align with the rebound thesis.

Evidence & confidence

Inclusion is based on analyst EPS expectations and prior-quarter comparison, not a new company event.

$MPCBullishHigh confidence
Context

Marathon Petroleum is singled out with an extreme EPS jump expectation, from $1.73 to $13.95 next week, and the system flags it bullish across the board.

Expected impact

High sensitivity to the print versus expectations; likely positive reaction if the rebound is confirmed.

Evidence & confidence

The text provides specific EPS figures and explicitly states the system’s bullish read, creating a clear pre-earnings positioning signal.

$FANGBullishMedium confidence
Context

Diamondback Energy is listed as expected to surge from $0.08 to $6.12 EPS, and the system flags it bullish.

Expected impact

Moderate-to-strong upside bias into the report if results track the steep estimate increase.

Evidence & confidence

The article gives specific directional EPS expectations but no new operational or guidance disclosure.

$LLYNeutralLow confidence
Context

Eli Lilly is included on the bearish screen because EPS is projected to be lower than the prior quarter, even though the article says it is not a concern.

Expected impact

Lower probability of a negative reaction if the market views the decline as non-structural; otherwise downside risk.

Evidence & confidence

The article provides no EPS numbers for LLY and is primarily a framework for interpretation rather than a new disclosure.

$EDNeutralLow confidence
Context

Consolidated Edison is also flagged as expected to earn less than the prior quarter, but the article frames the dip as not a downtrend.

Expected impact

Neutral-to-slight downside risk into earnings if the market treats the decline as worsening fundamentals.

Evidence & confidence

No specific ED EPS figures or new company event are provided, only inclusion in a screen.

Market effects

The article argues margin expansion is concentrated in Technology and Communication Services, while Health Care and parts of utilities lag, shaping relative-value expectations into earnings.

Primarily US-focused via S&P 500 sector margin discussion; limited direct regional specificity.

Limited. The thesis is US index and sector margin structure, with no direct global macro or cross-border deal details.

Counterpoint

Record margin claims may be skewed by sector composition and one-off items; earnings screens based on analyst EPS swings can misprice the quality of earnings.

Key entities

  • S&P 500 Index

    Used as the macro backdrop for record profit margins and sector dispersion.

  • Marathon Petroleum

    Highlighted with a very large expected quarter-over-quarter EPS jump and a bullish system read.

  • Constellation Energy

    Highlighted as bearish with a sharp expected EPS decline versus the prior quarter.

Related articles

$VSTMed

Vistra Profit Dips 7% on Hedging Costs; $1B AI Bet Planned

Vistra Corp reported Q2 2026 net income of $305 million, down 6.7% year over year, largely due to $472 million in unrealized hedging losses tied to commodity contracts. Adjusted core EBITDA rose 31% to $1.767 billion on higher demand and realized energy prices. Vistra plans up to $1 billion for Helix Digital Infrastructure and received FERC approval to acquire Cogentrix Energy.

$APOMed

ANALYSIS: Apollo wins the race for Easyjet, but what does it mean for passengers (and for Belfast)?

Apollo Global Management confirmed a recommended cash offer to buy EasyJet for about €6.6bn (£5.7bn), valuing shares at £7.15 each, expected to close in Q1 2027 subject to regulators. Apollo plans to use EasyJet’s slot portfolio and bases to restore growth; no jobs are expected to be cut in the first 12 months. Belfast routes are highlighted as highly exposed to any capacity changes.

$VSTMedAI 8/10

Vistra Corp Q2 Results: Adjusted EBITDA rises 31% despite earnings miss

Vistra Corp reported Q2 EPS of 91 cents versus $1.70 expected, with revenue down to $4.02B from $4.25B. GAAP net income fell to $305M as unrealized derivative losses rose $488M, though adjusted EBITDA increased 31% to $1.77B. Vistra reaffirmed 2026 adjusted EBITDA guidance of $6.8B to $7.6B and free cash flow before growth of $3.93B to $4.73B.

$MPCMed

El Paso leaders demand Marathon refinery answers after residents report noxious fumes

El Paso residents reported strong odors and fumes from a Marathon Petroleum refinery. Local officials, including City Rep. Josh Acevedo and County Commissioner David Stout, demanded transparency after Texas Commission on Environmental Quality (TCEQ) reports cited emissions far above permit limits, including 862 pounds of sulfur dioxide over 24 hours and releases of 1,3-butadiene and propylene. Marathon said it responded, deployed monitoring, and found no health risks.

$GILDMed

Weekly HIV Pill Held Viral Suppression as Well as Daily Therapy in Phase 3 Trial

Phase 3 ISLEND-1 results in the New England Journal of Medicine found a once-weekly tablet of islatravir 2 mg plus lenacapavir 300 mg was noninferior to once-daily bictegravir, emtricitabine, and tenofovir alafenamide for maintaining HIV viral suppression at 48 weeks in 607 adults already suppressed for at least 6 months. None on weekly therapy had HIV-1 RNA ≥50 copies/mL vs 0.3% on daily. Serious adverse events were 5.3% vs 4.6%.